The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

23 articles for FX Tavares


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
The discovery and optimization of pyrimidinone-containing MCH R1 antagonists.EBI
Glaxosmithkline
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.EBI
Glaxosmithkline
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.EBI
Glaxosmithkline
6-(4-chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-based melanin-concentrating hormone receptor 1 antagonist.EBI
Glaxosmithkline
Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1.EBI
Glaxosmithkline
Ketoheterocycle-based inhibitors of cathepsin K: a novel entry into the synthesis of peptidic ketoheterocycles.EBI
Glaxosmithkline
P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.EBI
Glaxosmithkline
Novel and potent cyclic cyanamide-based cathepsin K inhibitors.EBI
Glaxosmithkline
Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications.EBI
Glaxosmithkline
Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.EBI
Glaxosmithkline
Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.EBI
Glaxosmithkline
Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.EBI
Glaxosmithkline
Small molecule DCN1 inhibitors and therapeutic methods using the sameBDB
University of Michigan
Amide compounds for treatment of immune and inflammatory disordersBDB
Achillion Pharmaceuticals
Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitorsBDB
Jubilant Biosys
Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of diseaseBDB
Novartis
Bicyclic heteroaryl derivatives as CFTR potentiatorsBDB
Cystic Fibrosis Foundation Therapeutics
S-imino-S-oxo-iminothiadiazine compounds as BACE inhibitors, compositions, and their useBDB
Merck Sharp & Dohme
Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereofBDB
Boston College
Detecting a quasi-stable imine species on the reaction pathway of SHV-1 ß-lactamase and 6ß-(hydroxymethyl)penicillanic acid sulfone.BDB
Case Western Reserve University
Factor IXa inhibitorsBDB
Merck Sharp & Dohme
17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivative, use thereof, and medicament containing the derivativeBDB
TBA
Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one.BDB
Merck Research Laboratories